Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: A study in cortisol-secreting and -nonsecreting tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages

  Bonnet, Stéphane ^a,b,c   Gaujoux, Sébastien ^a,b,c   Launay, Pierre ^a   Baudry, Camille ^a,b   Chokri, Ilham ^c   Ragazzon, Bruno ^a,b   Libé, Rossella ^a,b,c,d   René Corail, Fernande ^a   Audebourg, Anne ^c   Vacher Lavenu, Marie Cécile ^b,c   Groussin, Lionel ^a,b,c,d   Bertagna, Xavier ^a,b,c,d   Dousset, Bertrand ^a,b,c,d   Bertherat, Jérôme ^a,b,c,d   Tissier, Frédérique ^a,b,c,d  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c COMETE INCA Rare Adrenal Cancer Network ^*  (France)

^d Rare Adrenal Cancer Network COMETE INCA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATENIN; HYDROCORTISONE; NUCLEIC ACID; WNT PROTEIN;

ADRENAL CORTEX ADENOMA; ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HYDROCORTISONE RELEASE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADULT; BETA CATENIN; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RNA, NEOPLASM; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 79951719257     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1885     Document Type: Article

References (39)

1. Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, Lavery GG, Parker KL, Hammer GD 2008 Targeted disruption of β-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 135:2593-2602
2. Gummow BM, Winnay JN, Hammer GD 2003 Convergence of Wnt signaling and steroidogenic factor-1 (SF-1) on transcription of the rat inhibin α gene. J Biol Chem 278:26572-26579 (Pubitemid 36876801)
3. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM, René-Corail F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, Perret C, Bertherat J 2005 Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65:7622-7627 (Pubitemid 41297234)
4. Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, Grimber G, Godard C, Terris B, Perret C 2008 Wnt/β-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol 4:647-660
5. Chiang JM, Chou YH, Chen TC, Ng KF, Lin JL 2002 Nuclear β-catenin expression is closely related to ulcerative growth of colorectal carcinoma. Br J Cancer 86:1124-1129 (Pubitemid 34438085)
6. Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J, Lowy AM 2002 β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 62:3503-3506 (Pubitemid 34651399)
7. Giles RH, van Es JH, Clevers H 2003 Caught up in a Wnt storm:Wnt signaling in cancer. Biochim Biophys Acta 1653:1-24 (Pubitemid 36627817)
8. Gregorieff A, Clevers H 2005 Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 19:877-890 (Pubitemid 40548056)
9. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J 2001 Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773
10. Reya T, Clevers H 2005 Wnt signalling in stem cells and cancer. Nature 434:843-850 (Pubitemid 40558990)
11. Gaujoux S, Tissier F, Groussin L, Libé R, Ragazzon B, Launay P, Audebourg A, Dousset B, Bertagna X, Bertherat J 2008 Wnt/β-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic β-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93:4135-4140
12. Semba S, Kusumi R, Moriya T, Sasano H 2000 Nuclear Accumulation of B-catenin in human endocrine tumors: association with Ki-67 (MIB-1) proliferative activity. Endocr Pathol 11:243-250
13. Tadjine M, Lampron A, Ouadi L, Bourdeau I 2008 Frequent mutations of β-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 68:264-270
14. Tadjine M, Lampron A, Ouadi L, Horvath A, Stratakis CA, Bourdeau I 2008 Detection of somatic β-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). Clin Endocrinol (Oxf) 69:367-373
15. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, Taketo MM, Tissier F, Bertherat J, Lefrançois-Martinez AM, Martinez A, Val P 2010 Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 19:1561-1576
16. Libè R, Fratticci A, Bertherat J 2007 Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13-28 (Pubitemid 47521719)
17. Bioulac-Sage P, Balabaud C, Zucman-Rossi J 2010 Subtype classification of hepatocellular adenoma. Dig Surg 27:39-45
18. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P 2006 Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515-524
19. Nunes ML, Vattaut S, Corcuff JB, Rault A, Loiseau H, Gatta B, Valli N, Letenneur L, Tabarin A 2009 Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. J Clin Endocrinol Metab 94:456-462
20. Weiss LM 1984 Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169 (Pubitemid 14166767)
21. Weiss LM, Medeiros LJ, Vickery Jr AL 1989 Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202-206 (Pubitemid 19081702)
22. Cadoret A, Ovejero C, Terris B, Souil E, Lévy L, Lamers WH, Kitajewski J, Kahn A, Perret C 2002 New targets of β-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21:8293-8301
23. Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney JA, Luton JP, Bertagna X, Stratakis CA, Bertherat J 2002 Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease(PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 71:1433-1442 (Pubitemid 36018745)
24. Bertherat J, Bertagna X 2009 Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 23:261-271
25. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521-531 (Pubitemid 36267859)
26. Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F, Soubrane O, Vacher-Lavenu MC, Perret C, Cavard C, Terris B 2007 Cholestasis is a marker for hepatocellular carcinomas displaying β-catenin mutations. J Pathol 212:345-352 (Pubitemid 47017988)
27. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767
28. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW 1997 Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275:1787-1790 (Pubitemid 27136715)
29. Seki M, Tanaka K, Kikuchi-Yanoshita R, Konishi M, Fukunari H, Iwama T, Miyaki M 1992 Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet 89:298-300
30. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J 1999 β-Catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 18:4044-4046
31. Lüchtenborg M, Weijenberg MP, Wark PA, Saritas AM, Roemen GM,van Muijen GN, de Bruïne AP, van den Brandt PA, de Goeij AF 2005 Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer 5:160
32. Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bapat B, Gallinger S, Redston M 1999 β-Catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59:3346-3351 (Pubitemid 29334489)
33. Miyaki M, Iijima T, Kimura J, Yasuno M, Mori T, Hayashi Y, Koike M, Shitara N, Iwama T, Kuroki T 1999 Frequent mutation of β-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 59:4506-4509 (Pubitemid 29428947)
34. Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, Maeda S, Ichinose M, Kanematsu T, Yamashita S 2002 Aberrant localization of β-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433-3440 (Pubitemid 34816401)
35. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW 1998 Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512 (Pubitemid 28425575)
36. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, Boman BM 2001 Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61:8664-8667 (Pubitemid 34013874)
37. Masi G, Lavezzo E, Iacobone M, Favia G, Palù G, Barzon L 2009 Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors. J Endocrinol Invest 32:597-600
38. Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC 2003CK2phosphorylation of the armadillo repeat region of β-catenin potentiates Wnt signaling. J Biol Chem 278:24018-24025
39. Lawnicka H, Kowalewicz-Kulbat M, Sicinska P, Kazimierczuk Z, Grieb P, Stepien H 2010 Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res 340:371-379